Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics (MLYS) granted equity inducement awards to a new non-executive employee on September 21, 2026, under its 2025 Employment Inducement Incentive Award Plan.

Rhea-AI Summary

Mineralys Therapeutics (MLYS) granted equity inducement awards to a new non-executive employee on September 21, 2026, under its 2025 Employment Inducement Incentive Award Plan.

The Compensation Committee approved a stock option covering 14,880 shares of common stock and a restricted stock unit (RSU) award covering 11,160 shares. The option vests over four years, with 25% of the shares vesting on the first anniversary of the September 21, 2026 vesting commencement date, and 1/48th vesting monthly thereafter, subject to continued service. The RSU award vests over four years in four equal annual installments starting on the first anniversary of the same commencement date, subject to continued service. The awards were made as inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Figures

Stock option award: 14,880 shares Restricted stock unit award: 11,160 shares Option vesting: Four years +1 more

Stock option award

14,880 shares

Inducement award to a new non-executive employee

Restricted stock unit award

11,160 shares

Inducement award to a new non-executive employee

Option vesting

Four years

25% on the first anniversary and 1/48th monthly thereafter

RSU vesting

Four years

25% on each of the first four anniversaries

Historical Context

2 past events · Latest: Sep 09

2 events

1. Sep 09

   Inducement awards

   24h Move

   -3.9%

   Awards granted to two new non-executive employees under the inducement incentive plan

2. Aug 13

   Inducement award

   24h Move

   -1.6%

   Equity awards granted to newly appointed chief medical officer under inducement plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), aldosterone synthase inhibitor

3 terms

restricted stock unit financial

"an inducement restricted stock unit award covering 11,160 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

aldosterone synthase inhibitor medical

"a highly selective aldosterone synthase inhibitor"

Aldosterone synthase inhibitors are drugs that reduce production of the hormone aldosterone, which helps control salt, water balance, and blood pressure. Think of them as turning down a faucet that feeds excess blood pressure and fluid buildup; by lowering aldosterone they can ease strain on the heart and kidneys. Investors track these drugs because trial results, regulatory approval, and safety can materially affect a developer’s revenue outlook and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, September 21, 2026, and 1/48th of the total shares underlying the award vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the award’s vesting commencement date, September 21, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

Source: Mineralys Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Under which equity plan were the inducement awards granted?

The inducement stock option and restricted stock unit awards were granted under the Mineralys 2025 Employment Inducement Incentive Award Plan, which provides for equity awards to new employees.

How does the vesting schedule work for the stock option award?

The stock option award vests over four years. 25% of the total shares vest on the first anniversary of the vesting commencement date, September 21, 2026, and 1/48th of the total shares vest after each subsequent one-month period, subject to the employee's continued service.

What is the vesting schedule for the restricted stock unit (RSU) award?

The restricted stock unit award vests over four years, with 25% of the RSUs vesting on each of the first four anniversaries of the vesting commencement date, September 21, 2026, subject to continued service.

Why were these awards classified as inducement grants under Nasdaq rules?

The company states that the awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).